Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ras interference as cancer therapy.

Anja M Duursma1, Reuven Agami

  • 1Division of Tumor Biology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.

Seminars in Cancer Biology
|October 18, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Histidine to glutamine substitutants, a regulated process that impacts cell survival and suggests histidine shortage in cancer.

Cell death discovery·2026
Same author

Arginine Deprivation of ASS1-Deficient Cancers Drives Mistranslation and Shared Neoepitope Production.

Cancer research·2026
Same author

Aspartyl-tRNA synthetase 1 (DARS1) reshapes hepatocellular carcinoma proteome and promotes aggressiveness through noncanonical SAGA-MYC signaling modulation.

Hepatology (Baltimore, Md.)·2026
Same author

MHC1-TIP enables single-tube multimodal immunopeptidome profiling and uncovers intratumoral heterogeneity in antigen presentation.

Communications biology·2026
Same author

Exploiting nanopore sequencing advances for tRNA sequencing of human cancer models.

NAR cancer·2025
Same author

Upstream open reading frame translation enhances immunogenic peptide presentation in mitotically arrested cancer cells.

Nature communications·2025
Same journal

Role of oral microbiome in cancer immunotherapy.

Seminars in cancer biology·2026
Same journal

Unveiling tumor heterogeneity by single cell RNA-sequencing: From basic considerations to clinical applications.

Seminars in cancer biology·2026
Same journal

Hidden architecture of resistance: The extracellular matrix in melanoma's immune landscape.

Seminars in cancer biology·2026
Same journal

Microfluidic technologies for extracellular vesicle isolation and analysis: Implications for translational applications in cancer therapy.

Seminars in cancer biology·2026
Same journal

Exploring glioblastoma microenvironment using organoids: opportunities, limitations, and emerging concepts.

Seminars in cancer biology·2026
Same journal

Special issue: Lipid metabolic alterations in cancer: Pathogenic mechanisms, therapies and common pathophysiology with cardiovascular disease.

Seminars in cancer biology·2026
See all related articles

Activating Ras mutations fuel cancer growth. RNA interference effectively silenced oncogenic K-Ras in tumor cells, demonstrating its therapeutic potential for cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Gene Therapy

Background:

  • Activating point mutations in the small GTPase Ras are found in approximately 30% of human cancers.
  • Constitutively active Ras promotes growth factor-independent cell proliferation and survival, driving tumor progression and maintenance.
  • Existing therapeutic strategies targeting Ras include farnesyltransferase inhibitors (FTIs) and antisense oligonucleotides.

Purpose of the Study:

  • To evaluate the potential of RNA interference (RNAi) as a novel therapeutic strategy for blocking oncogenic Ras.
  • To demonstrate the efficacy of an RNAi-mediating vector in specifically silencing the expression of oncogenic K-Ras in cancer cells.

Main Methods:

  • Utilized an RNAi-mediating vector designed to specifically target and silence endogenous human genes.

Related Experiment Videos

  • Applied the RNAi vector to tumor cells harboring oncogenic K-Ras mutations.
  • Assessed the stable suppression of oncogenic K-Ras expression.

    • Main Results:

    • The RNAi-mediating vector successfully and stably suppressed the expression of oncogenic K-Ras in treated tumor cells.
    • This suppression highlights the feasibility of using RNAi to target specific oncogenes.

    Conclusions:

    • RNA interference represents a promising new tool for inhibiting oncogenes in cancer therapy.
    • Stable suppression of oncogenic K-Ras via RNAi demonstrates its therapeutic potential in preclinical cancer models.